TLX (Telix Pharmaceuticals) Other Net Income (Loss): $-0.0 Mil (TTM As of Dec. 2025)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $10.89
GF Value $27.71
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Other Net Income (Loss)?

Telix Pharmaceuticals TLX +6.61% 50 Other Net Income (Loss) is $-0.0 Mil as of Dec. 2025. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $27.71 (Possible Value Trap). The stock has 6 warning signs investors should review.

Telix Pharmaceuticals's Other Net Income (Loss) for the six months ended in Dec. 2025 was $-0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.0 Mil.

Telix Pharmaceuticals's quarterly Other Net Income (Loss) increased from Dec. 2024 ($0.0 Mil) to Jun. 2025 ($0.0 Mil) but then declined from Jun. 2025 ($0.0 Mil) to Dec. 2025 ($-0.0 Mil).

Telix Pharmaceuticals Other Net Income (Loss) Related Terms

Telix Pharmaceuticals Other Net Income (Loss) Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Other Net Income (Loss) Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00
TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Other Net Income (Loss) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Net Income (Loss) of $-0.0 Mil mean?
Telix Pharmaceuticals (TLX) has a Other Net Income (Loss) of $-0.0 Mil as of Dec. 2025.
Is Telix Pharmaceuticals' Other Net Income (Loss) too high?
Telix Pharmaceuticals' current Other Net Income (Loss) is $-0.0 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Other Net Income (Loss) compare to VRTX and REGN?
Telix Pharmaceuticals' Other Net Income (Loss) of $-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Net Income (Loss) for a Biotechnology company?
A good Other Net Income (Loss) depends on the Biotechnology industry context. However, Other Net Income (Loss) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Net Income (Loss) mean?
A high Other Net Income (Loss) can signal that a stock is expensive relative to its fundamentals. Telix Pharmaceuticals's current Other Net Income (Loss) is $-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $27.71, compared to a current price of $10.89 — trading 60.7% below its estimated fair value. The current Other Net Income (Loss) is $-0.0 Mil. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Net Income (Loss) calculated?
Other Net Income (Loss) is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Other Net Income (Loss) is $-0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.89 is trading 60.7% below its estimated GF Value™ of $27.71. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Other Net Income (Loss): $-0.0 Mil
  • GF Value™: $27.71 vs. price of $10.89 (60.7% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Other Net Income (Loss) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.89
Price
$27.71
GF Value